Procter & Gamble Health Ltd
₹5015
-47.50 (0.94%)
Wed, 28 Oct 2026, 10:44 pm
Health Technology
Pharmaceuticals: Major
24.5KProcter & Gamble Health Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 13.32 | 11.14 | 5.64 | 10.96 | 8.09 | 14.80 | 18.81 | 15.50 | 13.77 | 16.65 | 30.57 | 24.12 | 20.91 | 22.78 | 6.10 | 39.86 | 52.52 | 36.10 | 37.97 | 36.41 |
| Price to book ratio | 3.81 | 2.94 | 1.91 | 1.78 | 1.13 | 2.05 | 3.43 | 2.41 | 2.23 | 1.78 | 2.38 | 2.19 | 2.49 | 2.92 | 3.32 | 7.45 | 13.20 | 11.28 | 11.61 | 15.90 |
| Price to sales ratio | 2.52 | 2.23 | 2.28 | 2.39 | 1.31 | 2.05 | 2.34 | 1.77 | 1.58 | 1.17 | 1.52 | 1.38 | 1.67 | 3.06 | 6.04 | 7.47 | 9.21 | 6.25 | 7.09 | 6.85 |
| Price to cash flow ratio | 12.05 | 11.37 | 9.28 | 12.49 | 15.29 | 14.86 | 13.34 | 0 | 15.51 | 46.51 | 54.70 | 12.97 | 13.48 | 29.10 | 0 | 22.81 | 35.13 | 38.74 | 34.83 | 48.54 |
| Enterprise value | 900Cr | 793Cr | 646Cr | 637Cr | 326Cr | 643Cr | 1047Cr | 875Cr | 862Cr | 720Cr | 1131Cr | 1063Cr | 1349Cr | 1791Cr | 3876Cr | 6112Cr | 8824Cr | 6629Cr | 8285Cr | 8355Cr |
| Enterprise value to EBITDA ratio | 8.61 | 7.39 | 8.26 | 9.64 | 6.72 | 10.68 | 14.18 | 21.51 | 8.52 | 9.79 | 19.89 | 12.45 | 10.72 | 18.67 | 25.98 | 28.28 | 34.89 | 24.47 | 25.18 | 19.32 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.02 | 0.01 |
| Return on equity % | 31.95 | 28.84 | 38.59 | 16.87 | 14.41 | 14.26 | 15.53 | 16.84 | 17.54 | 11.10 | 8.02 | 9.35 | 12.61 | 8.74 | 8.95 | 0 | 21.96 | 29.17 | 33.57 | 48.55 |
Procter & Gamble Health Ltd Ratios
The Procter & Gamble Health Ltd Ratios page provides a complete fundamental analysis of Procter & Gamble Health Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Procter & Gamble Health Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Procter & Gamble Health Ltd (NSE: PGHL, BSE: 500126) is currently trading at ₹5015, with a market capitalization of ₹8354.05Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Procter & Gamble Health Ltd remains a key stock for fundamental analysis using Procter & Gamble Health Ltd Ratios.
Procter & Gamble Health Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Procter & Gamble Health Ltd P/E ratio currently stands at 36.41, making it one of the most tracked metrics in Procter & Gamble Health Ltd Ratios.
Historically, the Procter & Gamble Health Ltd P/E ratio has shown strong fluctuations:
- 2025: 36.41
- 2024: 37.97
- 2023: 36.10
- 2022: 52.52
- 2021: 39.86
The decline in Procter & Gamble Health Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Procter & Gamble Health Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 15.90.
Historical P/B trend:
- 2025: 15.90
- 2024: 11.61
- 2023: 11.28
- 2022: 13.20
Procter & Gamble Health Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Procter & Gamble Health Ltd P/S ratio currently stands at 6.85, an important part of Procter & Gamble Health Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 6.85
- 2024: 7.09
- 2023: 6.25
- 2022: 9.21
A stable or declining Procter & Gamble Health Ltd P/S ratio indicates cautious market sentiment.
Procter & Gamble Health Ltd Price to Cash Flow Ratio (P/CF)
The Procter & Gamble Health Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 48.54.
Historical Procter & Gamble Health Ltd Price to Cash Flow Ratio:
- 2025: 48.54
- 2024: 34.83
- 2023: 38.74
- 2022: 35.13
- 2021: 22.81
The rising Procter & Gamble Health Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Procter & Gamble Health Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Procter & Gamble Health Ltd EV currently stands at ₹8355Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 8355Cr
- 2024: 8285Cr
- 2023: 6629Cr
- 2022: 8824Cr
Procter & Gamble Health Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Procter & Gamble Health Ltd EV/EBITDA ratio is currently 19.32, a key metric in Procter & Gamble Health Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 19.32
- 2024: 25.18
- 2023: 24.47
- 2022: 34.89
Stable Procter & Gamble Health Ltd EV/EBITDA indicates balanced valuation.
Procter & Gamble Health Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Procter & Gamble Health Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.01
- 2024: 0.02
- 2023: 0
- 2022: 0.01
Procter & Gamble Health Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Procter & Gamble Health Ltd ROE currently stands at 48.55%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 48.55
- 2024: 33.57
- 2023: 29.17
- 2022: 21.96
Procter & Gamble Health Ltd demonstrates strong profitability and efficient capital utilization.
Procter & Gamble Health Ltd Ratios Analysis Summary
The Procter & Gamble Health Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Procter & Gamble Health Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Procter & Gamble Health Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
